Skip to main content

Table 3 Factors associated with anxiety during an antiviral treatment for hepatitis C virus (HCV) infection at week 12 and at week 24

From: Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C

Characteristics Week 12 Week 24
β (95% CI) Wald χ2 p-value β (95% CI) Wald χ2 p-value
Treatment group (Group 1 vs. Group 2) 1.07 (0.45–2.56) 0.021 0.884 0.88 (0.38–2.02) 0.088 0.767
Sex (female vs. male) 0.89 (0.34–2.35) 0.055 0.815 0.90 (0.38–2.14) 0.059 0.808
Age at recruitment (year) 0.97 (0.94–1.01) 1.911 0.167 0.98 (0.94–1.01) 1.899 0.168
Body weight (kg) 0.99 (0.95–1.02) 0.624 0.430 0.99 (0.95–1.03) 0.326 0.568
Alcohol use disorder 2.07 (0.58–7.42) 1.235 0.266 1.48 (0.46–4.78) 0.430 0.512
Number of physical comorbidities 1.28 (1.01–1.62) 4.303 0.038* 1.21 (0.96–1.53) 2.581 0.108
α-fetoprotein level (ng/mL) 1.00 (0.99–1.02) 0.123 0.726 0.98 (0.94–1.01) 2.403 0.121
Genotype of HCV (non- 1 vs. 1) 0.66 (0.27–1.63) 0.801 0.371 0.70 (0.28–1.72) 0.615 0.433
Ribavirin daily dose (g/day) 1.20 (0.24–6.00) 0.052 0.820 1.95 (0.67–5.64) 1.505 0.220
Poor treatment response (HCV RNA positive) 1.45 (0.60–3.50) 0.669 0.414 1.53 (0.61–3.82) 0.832 0.362
  1. Note: Group 1, patients who were treated with PegIFN-α-2a plus ribavirin; Group 2, patients who were treated with PegIFN-α-2b plus ribavirin; Anxiety, HADS anxiety score ≥ 8; 95% CI, 95% confidence interval
  2. *p < 0.05